QIAGEN NV

Mar 28, 2021 — NeuMoDx FDA EUA

QIAGEN's NeuMoDx multiplex test received FDA Emergency Use Authorization, validating the NeuMoDx platform acquired earlier. [57] This reinforced the company's expansion into clinical PCR capabilities and its pivot away from COVID-only exposure. Investors viewed NeuMoDx as a strategic asset for clinical molecular diagnostics. [57], [59] The regulatory clearance reduced execution risk and triggered a short-term rally.

Feb 8, 2022 — Q4 2021 and full-year results; 2022 outlook

Q4 2021 net sales reached $582M; full-year 2021 grew 19% in constant exchange rate (CER) to approximately $2.25B, exceeding guidance. [1], [2], [4] Management highlighted strong non-COVID portfolio growth at roughly 22% CER but guided for a significant decline in COVID-19 product sales in 2022, while expecting double-digit CER growth across non-COVID segments. [1], [2], [4]

The narrative shifted from "COVID boom" to a credible diversified growth story anchored in non-COVID product recovery and the company's "five pillars" strategy. [1], [2], [44] Post-earnings sentiment drove a rally and transition into a new uptrend as investors re-rated recurring non-COVID revenues.

May 11, 2022 — Acquisition of majority stake in BLIRT S.A.

QIAGEN acquired approximately 96% of BLIRT, a recombinant enzymes and manufacturing company, strengthening Sample Technologies and reagent supply. [37] The company stated the deal had no material impact on 2022 outlook. [37]

This was viewed as tactical vertical integration to secure reagent supply and margin control in Sample Technologies, reinforcing the industrialization angle of the five-pillars plan. [37], [39] Market reaction was positive but muted, with consolidation and range-bound trading as investors digested the strategic fit.

Q2 2022 (reported July 26, 2022) — Non-COVID growth vs. COVID decline

Q2 2022 net sales fell 4% CER to $516M. [3] Non-COVID product sales grew 10% CER to approximately $423M, while COVID product sales declined roughly 39% CER to about $92M. [3] The company tightened and then raised parts of its outlook as trends clarified. [3]

This reinforced investor conviction that QIAGEN was successfully pivoting to sustainable, non-COVID drivers, though it confirmed ongoing volatility from pandemic-related revenues. [3], [44] Markets began valuing the company on underlying pillars rather than transitory COVID volumes. Trading remained volatile with episodic drawdowns when COVID sales disappointed and rallies on non-COVID beats.

Jan 9, 2023 — Verogen acquisition completed

QIAGEN completed acquisition of Verogen, a next-generation sequencing human-ID and forensics platform, for $150M cash with expected Verogen sales of roughly $20M in 2023. [25], [31]

The deal signaled targeted M&A to bolster the Human-ID/Forensics pillar and broaden NGS-based, higher-growth adjacencies. [25], [31] Investors treated it as strategically logical and modestly accretive over time, driving mild positive re-rating in the relevant growth segments. The stock entered a gradual uptrend as M&A demonstrated disciplined, pillar-aligned deployment.

Feb 7, 2023 — FY-2022 results & FY-2023 guidance

Q4 FY-2022 results were released alongside FY-2023 guidance: net sales of at least $2.05B CER and adjusted diluted EPS of at least $2.10 CER, with continued double-digit CER growth in non-COVID pillars offset by declining COVID revenues. [26]

Management reaffirmed the five-pillars strategy (Sample Technologies, QIAcuity, QIAstat-Dx, NeuMoDx, QuantiFERON), reinforcing the narrative of a multi-pillar, mid-cap compounder with clearer organic drivers. [26], [40], [46] Guidance removed some uncertainty about 2023 revenue composition, shifting sentiment from range-bound to cautiously constructive.

Throughout 2023 — Execution on five pillars; product momentum

Continued commercial push across QIAcuity (digital PCR), QIAstat-Dx (syndromic testing), QuantiFERON, NGS/human-ID initiatives and Sample Technologies. [39], [40], [43], [46] Management emphasized targeted M&A and commercialization execution.

Investor perception evolved toward a "focused growth" story with diversified end markets, recurring consumables, and selective system rollouts. [39], [43] Analysts began valuing the recurring consumables mix and higher-margin pillars more explicitly. The stock entered a gradual uptrend as execution validated the strategy, with episodic volatility around macro and diagnostic demand news.

Jun 2024 (early June) — Decision to discontinue NeuMoDx business; restructuring

QIAGEN announced discontinuation of NeuMoDx integrated PCR systems and a pre-tax restructuring charge of roughly $400M (predominantly non-cash items recognized in Q2 2024). [61], [53], [60] The company committed to customer support during transition.

Short-term investor disappointment reflected execution concerns, but longer-term interpretation shifted to decisive portfolio rationalization—management proved willing to take one-time charges to free resources for higher-return pillars. [53], [61] Market sentiment moved from uncertainty to selective optimism about margin benefit and opportunity redeployment. The stock experienced a sharp drawdown on announcement, then stabilized as investors priced the restructuring and potential margin benefit.

Jun 17, 2024 — 2028 strategy announced (profitability + growth)

QIAGEN published a 2028 strategic plan focused on "solid profitable growth" with planned new instrument launches and reinvestment into core pillars. [49]

This repositioned the company toward disciplined growth and higher margin outcomes after NeuMoDx pruning. [49], [47] Investors increasingly framed QIAGEN as a focused diagnostics and sample-technology platform with clearer capital allocation. The stock recovered into a renewed uptrend as the market rewarded clearer strategic direction.

Q3 2024 (reported Nov 2024) — Execution shows margin improvement

Q3 2024 results came in ahead of outlook; management raised full-year expectations and adjusted operating income margin improved to roughly 29.6%, with the NeuMoDx decision cited as a contributor to efficiency gains. [63]

Evidence that restructuring and refocus were improving profitability shifted sentiment from "execution risk" to "operational leverage," with credibility returning to the management story. [63] The stock broke out higher as improving margins and raised guidance underpinned investor confidence.

Nov 4–5, 2025 — Parse Biosciences transaction and CEO succession announced

QIAGEN agreed to acquire Parse Biosciences (single-cell technologies) for approximately $225M upfront plus up to $55M in milestones. [33], [34] The company disclosed that CEO Thierry Bernard will step down once a successor is appointed. [33], [34]

M&A signaled continued discipline and a clear tilt toward higher-growth, high-margin platforms. [33], [34] The simultaneous management transition introduced near-term uncertainty over execution but signaled a planned leadership handover rather than abrupt change. Market reaction was mixed: strategic upside acknowledged, governance and transition risk priced in. Short-term volatility ensued with potential for renewed uptrend contingent on integration and successor clarity.

Mid-2026 (as of 2026-07-11) — Current market posture and price

Share price stands at 36.405. The company is executing its 2028 strategy, investing in QIAcuity, QIAstat-Dx, Sample Technologies, QuantiFERON and targeted M&A (Verogen, Parse). [25], [33], [49], [63]

Markets frame QIAGEN as a refocused molecular-diagnostics and life-sciences platform with improving margins after the 2024 restructuring and selective bolt-on deals. [63], [49], [25] Sentiment is constructive but sensitive to instrument placements and consumables growth persistence. The stock consolidates in the mid-30s range with directional bias dependent on execution of the 2028 plan and integration milestones.